Paul Conyngham’s dog Rosie was given months to live. Chemotherapy failed. Immunotherapy failed. So the Sydney tech entrepreneur did something unconventional — he usedChatGPT and computational genomicsto help design a personalized mRNA cancer vaccine for her specific tumor mutations. Several of Rosie’s tumors shrank.
https://x.com/paul_conyngham/status/2087223666778272070
That experiment is now a company. Gamgee launched as part ofY Combinator’s Summer <a href="https://bitcomme.com/a-complete-guide-for-brands-in-2026/” title=”A Complete Guide for Brands in 2026″>2026 batch, offering personalized mRNA cancer vaccines for dogs. The startup is running clinical trials in Australia and accepting cases from pet owners globally. Here’s how the science works and what the medical community thinks about it.
How ChatGPT Helped Design a Cancer Vaccine
The process behind Rosie’s vaccine wasn’t as simple as asking ChatGPT to cure cancer. It isa multi-step scientific workflow that Conyngham developed, combining AI tools with established genomics techniques.
The first step is sequencing. Scientists take samples from both the tumor and healthy tissue, then sequence the DNA of each. Comparing the two genomes reveals the specific mutations driving that individual cancer — the genetic changes that make cancer cells different from normal cells.
ChatGPT’s role comes in the analysis phase. Conyngham used the AI to help identify which mutations are most likely to be recognized by the immune system. Not every mutation makes a good vaccine target. The AI helped sort through the genomic data to find mutations that would produce proteins the immune system could learn to attack.
https://x.com/paul_conyngham/status/2032951638290530502
The final step is vaccine design. Based on the identified targets, scientists at UNSW’s RNA Institute synthesized an mRNA sequence that teaches the dog’s immune system to recognize and destroy cells carrying those specific mutations. The mRNA approach — the same technology behind COVID-19 vaccines from Moderna and BioNTech — instructs cells to produce small protein fragments that trigger an immune response without causing disease.
Noted that Rosie’s vaccine is believed to be the first fully computationally designed mRNA cancer vaccine ever delivered to a dog. The “fully computationally designed” distinction matters — it means AI was involved throughout the design pipeline, not just at one step.
Sam Altman Took Notice
The story gained significant attention in the AI community. OpenAI CEO Sam Altman met with Conyngham in March after the initial results went viral, saying the story had him thinking “this should be a company.” That meeting reportedly helped catalyze the transition from personal project tostartup.
https://x.com/sama/status/2037396826060673188
Y Combinator’s acceptance validates the commercial potential. The accelerator’s Summer 2026 batch includes Gamgee alongside dozens of other AI-focused startups, but few combine AI with such a direct biological application. The company’s positioning — personalized cancer treatment for pets — sits at the intersection of veterinary medicine, AI, and mRNA technology.
Personalized mRNA cancer vaccines for humans are already in clinical trials at companies like Moderna and BioNTech.ChatGPT’s growing rolein scientific research has been well documented throughout 2026. Gamgee essentially applies both trends to veterinary oncology, where regulatory barriers are lower and treatment timelines are faster.
What Oncologists Say About the Approach
Not everyone shares the optimism.The Conversation published an analysisfrom an oncologist urging caution about drawing broad conclusions from a single case.
The core concern is sample size. One dog responding positively to a treatment doesn’t prove the approach works reliably. Cancer is heterogeneous — different tumor types, different mutation profiles, different immune responses. What worked for Rosie’s specific cancer may not translate to other dogs with different tumor genetics.
There’s also the question of attribution. Tumors can sometimes shrink temporarily for reasons unrelated to treatment — a phenomenon oncologists call spontaneous regression. Without a controlled study comparing vaccinated dogs to unvaccinated ones with similar cancers, it’s difficult to confirm that the mRNA vaccine caused the tumor shrinkage.
The oncologist also flagged concerns about using AI for vaccine target selection without extensive validation. AI models can identify patterns in genomic data, but they can also produce false positives — mutations that look like good targets but don’t actually trigger an effective immune response in practice.
These are legitimate scientific concerns, not dismissals. The clinical trials Gamgee is now running in Australia should address them directly. Controlled studies with multiple dogs across different cancer types will determine whether the approach is broadly effective or a fortunate one-off.
How Gamgee’s Process Works for Pet Owners
For dog owners interested in Gamgee’s service, the process starts with a veterinary referral. The dog’s tumor and healthy tissue are sampled and sent for genomic sequencing. Gamgee’s platform — powered by computational genomics and AI analysis — identifies the optimal vaccine targets.
The mRNA vaccine is then synthesized specifically for that individual dog’s cancer mutations. No two vaccines are the same, because no two cancers have identical mutation profiles. After synthesis, the vaccine is administered by a veterinarian.
The company is running formal clinical trials in Australia while also accepting individual cases globally. The global acceptance suggests Gamgee is using a compassionate-use framework for dogs that have exhausted standard treatment options — similar to how experimental human treatments become available to terminal patients before formal approval.
Pricing and availability details haven’t been publicly disclosed. Personalized mRNA vaccine production is expensive — each vaccine requires individual sequencing, analysis, and synthesis. TheAI funding landscape in 2026suggests Gamgee likely has runway to subsidize early cases while building clinical evidence.
Why Veterinary AI Matters Beyond Pets
Gamgee’s approach has implications beyond veterinary medicine. If personalized mRNA cancer vaccines prove effective in dogs across multiple cancer types, the data could accelerate human clinical trials. Dogs develop many of the same cancers humans do — lymphoma, melanoma, osteosarcoma — and their shorter lifespans mean treatment outcomes become visible faster.
This “one health” approach — using veterinary medicine to inform human medicine — has precedent. Several human cancer treatments were first tested in dogs. The regulatory path is also simpler: veterinary treatments face fewer approval hurdles than human drugs, allowing faster iteration on vaccine design and delivery protocols.
Whether Gamgee succeeds or fails, the story illustrates something meaningful about AI’s role in 2026. A tech entrepreneur with no formal medical training used publicly available AI tools and academic collaborators to develop a novel cancer treatment. The barriers to biological innovation are dropping, and that’s simultaneously exciting and worth approaching with scientific rigor.
What is Gamgee and how does it use ChatGPT?
Gamgee is a Y Combinator-backed startup that creates personalized mRNA cancer vaccines for dogs. Founder Paul Conyngham usedChatGPT and computational genomicsto help identify cancer-driving mutations and design vaccine targets for his dog Rosie.
Did the mRNA vaccine actually cure the dog’s cancer?
Several of Rosie’s tumors shrank after receiving the vaccine, but oncologistsurge cautionabout concluding it’s a cure from one case. Clinical trials are underway to test the approach across multiple dogs and cancer types.
How can I get Gamgee’s vaccine for my dog?
Gamgee runs clinical trials in Australia andaccepts cases globally. Contact the company through their website with a veterinary referral. The service is typically for dogs that have exhausted standard treatment options.
Is Gamgee backed by Y Combinator?
Yes. Gamgee was accepted intoY Combinator’s Summer 2026 batch. OpenAI CEO Sam Altman also met with founder Paul Conyngham after the story went viral.
Can this mRNA vaccine approach work for human cancer?
Personalized mRNA cancer vaccines for humans are already in clinical trials at companies like Moderna and BioNTech. Gamgee’s veterinary data couldinform human researchsince dogs develop many of the same cancers humans do.
